UFT plus carboplatin for head and neck cancer

Masato Fujii, Yoshihiro Ohno, Yutaka Tokumaru, Yorihisa Imanishi, Minoru Kanke, Toshiki Tomita, Taku Yamashita

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer. The 5-year survival rate of those treated with UFT vs those not treated was 71.4% vs 23.8%, respectively. In the second study we developed the carboplatin plus UFT regimen - as a modification of cisplatin plus 5-FU -and studied its efficacy and toxicity in patients with advanced head and neck squamous cell carcinoma. These patients received UFT plus carboplatin. The objective response rate was 53.1%; grade ≥ 3 leukopenia, anemia, and thrombocytopenia were rare. These findings suggest that UFT plus carboplatin in the outpatient setting is feasible for patients with head and neck squamous cell carcinoma.

Original languageEnglish
Pages (from-to)72-75
Number of pages4
Issue number10 SUPPL. 9
Publication statusPublished - 2000 Dec 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'UFT plus carboplatin for head and neck cancer'. Together they form a unique fingerprint.

Cite this